News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

7TM Pharma And Synaptic Pharmaceutical, (SNAP) A Wholly Owned Subsidiary Of Lundbeck, Announces Collaborative Agreement On Novel Drug Targets


10/19/2005 5:09:40 PM

7TM Pharma and Synaptic have signed a collaborative agreement under which 7TM Pharma will apply its structure based drug discovery approach, Site-Directed Drug Discovery®, on 7TM receptors provided by Synaptic. Under the agreement, Synaptic has granted 7TM Pharma access to selected 7TM receptor drug targets with the right to pursue drug discovery and development on these drug targets. Synaptic has received options to obtain the exclusive rights to resulting drug discovery and development projects within Central Nervous System disorders against upfront payment, milestones and royalties.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES